Rekvina Pharmaceuticals (India) Private Limited, a active private limited company, was established on 04 May 2007 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24230MH2007PTC170589. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹5.00 M and a paid-up capital of ₹5.00 M.
It upholds a compliant status. Employing 47 professional, Its leadership includes Surbhit Mukesh Shah (Director), Mukesh Jamnadas Shah (Director), Amit Mukesh Shah (Director). It holds no open charges and ₹7.50 M settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 161, Kika Street, 1St Floor,, Mumbai, Maharashtra, 400004.
U24230MH2007PTC170589
170589
04 May 2007
₹5.00 M
₹5.00 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Rekvina Pharmaceuticals (India) Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Surbhit Mukesh Shah | Director | 04 May 2007 | Current |
| Mukesh Jamnadas Shah | Director | 04 May 2007 | Current |
| Amit Mukesh Shah | Director | 20 Sep 2024 | Current |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Rekvina Pharmaceuticals (India) Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 64.75% decrease. The company also saw a substantial fall in profitability, with a 1256.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 2084.19%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2020, Rekvina Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹7,500,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 May 2010 | Bank Of Baroda | ₹7.50 M | Satisfied |
Explore comprehensive loan charge details -
Rekvina Pharmaceuticals (India) has a workforce of 47 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Rekvina Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rekvina Pharmaceuticals (India)'s trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Rekvina Pharmaceuticals (India) Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Progress on Amit Mukesh Shah was appointed as a Director was appointed as a Director on 20 Sep 2024 & has been associated with this company since 1 year 2 months . was documented.
Rekvina Pharmaceuticals (India) Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was recorded as a recent event.
Progress on A charge registered on 18 May 2010 via Charge ID 10223369 with Bank Of Baroda was fully satisfied on 22 Mar 2022. was documented.
Progress on A charge with Bank Of Baroda amounted to Rs. 7.50 M with Charge ID 10223369 was registered on 18 May 2010. was documented.
Progress on Surbhit Mukesh Shah was appointed as a Director was appointed as a Director on 04 May 2007 & has been associated with this company since 18 years 6 months . was documented.
The CIN of Rekvina Pharmaceuticals (India) Private Limited is U24230MH2007PTC170589.
Rekvina Pharmaceuticals (India) Private Limited is headquartered at 161, Kika Street, 1St Floor,, Mumbai, Maharashtra, 400004.
Rekvina Pharmaceuticals (India) Private Limited was incorporated on 04 May 2007.
The current directors of Rekvina Pharmaceuticals (India) Private Limited are
The primary industry of Rekvina Pharmaceuticals (India) Private Limited is Manufacturing.
Rekvina Pharmaceuticals (India) Private Limited is unlisted.
The authorized capital of Rekvina Pharmaceuticals (India) Private Limited is ₹5.00 M, and the paid-up capital is ₹5.00 M.
The compliance status of Rekvina Pharmaceuticals (India) Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
_PRIVATE_LIMITED.webp)
Company Details
+91-XXXXXXXXXX